Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2059264 | 0.83 | CYP2C19 (0.40) | TSHRGRIN2BRAB9AALDH1A1CYP3A4 | |
| SCHEMBL2059327 | 0.79 | GRIN2B (0.38) | TSHRGRIN2BMAPTALDH1A1CYP3A4 | |
| SCHEMBL2059309 | 0.73 | MAPK1 (0.49) | TSHRALDH1A1MAPK1KMT2A | |
| SCHEMBL2439748 | 0.72 | USP30 (0.47) | — | |
| SCHEMBL2059409 | 0.72 | MMP2 (0.46) | TSHRGRIN2BMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL22694559 | 0.70 | SRD5A2 (0.42) | MAPTRAB9ASMN1; SMN2ALDH1A1CA1 | |
| SCHEMBL17542442 | 0.69 | OPRD1 (0.58) | TSHRMAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL16147114 | 0.69 | EPHX2 (0.61) | TSHRMAPTRAB9ACA1CA2 | |
| SCHEMBL31171531 | 0.69 | TSHR (0.43) | TSHRMAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL31171617 | 0.69 | TSHR (0.43) | TSHRMAPTRAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968733-B2 | Pyrrolidine analogue for preventing neurogenic pain and method for production thereof | GIFU UNIVERSITY (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20090306407-A1 | Pyrrolidine analogue for preventing neurogenic pain and method for production thereof | GIFU UNIVERSITY (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2058301-A1 | PYRROLIDINE ANALOGUE FOR PREVENTING NEUROGENIC PAIN AND METHOD FOR PRODUCTION THEREOF | Gifu University (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306407-A1 | Pyrrolidine analogue for preventing neurogenic pain and method for production thereof | HNMT, OPRK1, OPRL1 | TSHR 4643/4885GRIN2B 1048/4885MAPT 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.